DRI Capital

What is DRI Capital?

DRI Capital is a private equity firm established in 1992 and headquartered in Toronto, Canada. They are a pioneer in pharmaceutical royalty monetization and have a strong focus on creating a diversified portfolio of interests in medicines, particularly those that address unmet medical needs. With a history of tailored offerings, DRI Capital is known as a partner of choice for investors and innovators, consistently seeking creative and flexible structures to meet the unique requirements of their counterparties.

They have multiple repeat deal partners, evidencing their reputation in the industry.

Their strategic investments encompass royalty entitlements on medical devices, diagnostic products, life science tools, and technologies, further driving value creation by actively sourcing royalty streams on medically necessary products that possess long-term patent protection and exhibit high growth potential.

As a sophisticated capital allocator, DRI Capital specializes in acquiring dependable, patent-protected cash flow streams derived from the sales of significant drugs across diverse therapeutic areas. For investors, they offer exposure to a risk-mitigated, diversified portfolio of therapeutic assets aimed at generating attractive returns and showcasing considerable growth potential. DRI Capital has an extensive commitment to responsible investment and values ethical dealings in their operations, and they have offices located in Toronto, New York, and New Jersey.